Advanced Glycation End Products Market, By Type (Non-fluorescent AGEs and Fluorescent AGEs), By Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024

Code : CMI4350

Pages :105

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges: Side effects associated with available treatments

The side effects associated with available treatments can hamper the global advanced glycation end products market growth. Currently, there are limited treatment options available for managing AGEs and their related health issues. Many of the existing drugs and therapies have undesirable side effects that discourage patients from opting for long-term treatment. Most AGE inhibitors that are prescribed to reverse or slow down the glycation process often interact with other drugs and herbal supplements. This leads to harmful drug-drug interactions in the body. For example, aminoguanidine is one of the early generation AGE inhibitors but was not approved for clinical use due to safety concerns over potential side effects like immunosuppression. ALT-946 (alagebrium) showed promise in clinical trials for reducing heart disease risks in diabetic patients. However, its development was discontinued as it was found to cause adverse reactions like low blood pressure, diarrhea, bone fractures and others.

Market Opportunities: Increasing demand for personalized medicines

Increasing demand for personalized medicines can offer great opportunity for global advanced glycation end products market growth. With rising precision medicine and increased focus on targeting treatment based on an individual's genetic profile and biomarkers, there has been huge demand for personalized diagnostics and therapies tailored to unique patient needs. Advanced techniques for analyzing are especially relevant here as these biomarkers can provide valuable insight into pathological conditions on a patient-specific level. As genetics and molecular biology continue to transform healthcare, AGEs are poised to play an important role in the development of personalized medicines. Certain AGE structures have been shown to correlate with susceptibility to various diseases and treatment responses. Their measurement could help stratify patients and guide clinicians towards optimized therapeutic strategies for each individual. This would represent a paradigm shift away from conventional one-size-fits-all approaches, instead facilitating more precise and targeted clinical decision making. Pharmaceutical companies have taken note and several are actively pursuing R&D efforts to discover novel AGE-modulating drugs with applications in personalized therapies.